JPRN-jRCT2071230095招募中3 期
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide(CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib andDexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM):SUCCESSOR-2
Engelhardt Brian0 个研究点目标入组 41 人开始时间: 2023年11月25日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Participant has documented diagnosis of Multiple Myeloma and measurable disease.
- •Participant has received at least 1 prior line of anti-myeloma therapy.
- •Participant must have received prior treatment with lenalidomide and at least 2 cycles of
- •an anti-CD38 monoclonal antibody.
排除标准
- •Participant who has had prior treatment with mezigdomide or carfilzomib.
- •Participant has previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of initiating
- •study intervention.
研究者
相似试验
招募中
3 期
Open-label Study Comparing CC-92480 (BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)CTRI/2023/08/056910BRISTOL MYERS SQUIBB INDIA PRIVATE LIMITED
招募中
1 期
Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: SUCCESSOR-2Relapsed or Refractory Multiple Myeloma (RRMM)MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104CTIS2022-500861-29-00Celgene Corp.493
招募中
1 期
A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment.Relapsed or Refractory Multiple Myeloma (RRMM)MedDRA version: 25.0Level: LLTClassification code: 10086466Term: Relapsed/refractory multiple myeloma Class: 100000004848CTIS2023-509859-13-00Celgene Corp.874
进行中（未招募）
1 期
A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, and Dexamethasone in patients with a non-responsive or progressive blood cancer called Multiple MyelomaRelapsed or Refractory Multiple Myeloma (RRMM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000431-49-FICelgene Corporation864
进行中（未招募）
1 期
A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, and Dexamethasone in patients with a non-responsive or progressive blood cancer called Multiple MyelomaRelapsed or Refractory Multiple Myeloma (RRMM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000431-49-NOCelgene Corporation864